(Q38453368)

3 September 2017

title

Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis (English)

1 reference

3 September 2017

1 reference

1 reference

12

Alan W Partin

1 reference

3 September 2017

Lori J Sokoll

1

1 reference

3 September 2017

Daniel W Chan

2

1 reference

3 September 2017

Stephen D Mikolajczyk

3

1 reference

3 September 2017

Harry G Rittenhouse

4

1 reference

3 September 2017

Cindy L Evans

5

1 reference

3 September 2017

Harry J Linton

6

1 reference

3 September 2017

Leslie A Mangold

7

1 reference

3 September 2017

Phaedre Mohr

8

1 reference

3 September 2017

Georg Bartsch

9

1 reference

3 September 2017

Helmut Klocker

10

1 reference

3 September 2017

Wolfgang Horninger

11

1 reference

3 September 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

3 September 2017

1 reference

3 September 2017

volume

61

1 reference

3 September 2017

issue

2

1 reference

3 September 2017

page(s)

274-276

1 reference

Longitudinal screening for prostate cancer with prostate-specific antigen

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902398-1

7 January 2021

Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902398-1

7 January 2021

Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902398-1

7 January 2021

Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902398-1

7 January 2021

Free prostate-specific antigen in serum is becoming more complex

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902398-1

7 January 2021

A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902398-1

7 January 2021

"BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902398-1

7 January 2021

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902398-1

7 January 2021

Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902398-1

7 January 2021

10.1016/S0090-4295(02)02398-1

Identifiers

DOI

1 reference

3 September 2017

1 reference